Acadia Healthcare’s Survival Strategy? Activist Investor Khrom Capital Pushes For Full-Scale Sale!

Acadia Healthcare faces mounting pressure from Khrom Capital Management LLC, a 5.5% shareholder, which has launched an activist campaign urging the company to explore strategic alternatives, including a potential sale. This comes amid prolonged underperformance, a burdensome debt profile, and investor dissatisfaction. In a strongly worded letter to Acadia’s board, Khrom pointed to a 71% stock price decline over the past three years and echoed calls from another activist, Engine Capital, which recently took a 3% stake. The letter criticized entrenched board governance, including Reeve B. Waud’s 20-year tenure and a staggered board structure lasting until 2029. Khrom argues the company is undervalued, citing a current valuation of just 0.74x book value and ongoing profitability. Meanwhile, Acadia is navigating complex challenges including federal investigations and regulatory changes, while trying to stabilize operations following recent earnings showing soft same-facility volume growth and Medicaid pressures. Analysts remain divided, with UBS reiterating a Buy rating, while BofA downgraded to Neutral over looming Medicaid risks. The tension between strategic continuity and operational turbulence has now brought M&A into sharp focus.